FierceBiotech16h
Rivus reveals data to back up muscle-sparing claims of phase 2 obesity drug
Rivus already announced in August that the trial hit its key endpoint, but today fleshed out that win with some figures.
STAT10d
Novo’s new obesity drug shows modest results, raises concerns of psychiatric side effects
A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...
Roche Confirms Narrowed Pharma Focus, Fast Tracks Obesity-Drug Candidate -- Update
Roche said it plans to focus on five key therapeutic areas as part of its new pharma strategy through 2030. The company will prioritize work in the areas of neurology, oncology and hematology, ...
Research That Led to Obesity Drugs Wins Major Medical Prize
Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...
Morningstar7d
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
While initially approved for diabetes, GLP-1 drugs are gaining new indications, including the large opportunity in ...
Obesity drug developer BioAge Labs aims up to $640 mln valuation in upsized US IPO
BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the ...
New weight loss drugs spark eating disorder concerns in teens
BOSTON - There is concern over the newest weight loss drugs sparking eating disorders in teens. Newer GLP-1 weight loss drugs ...
Analysts say market forces will lower cost of obesity drugs
Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.
Severe obesity is on the rise in the US
Obesity is high and holding steady in the U.S. About 4 in 10 Americans have obesity overall and about 1 in 10 have severe ...
The Post-Journal1h
New CDC Population Data From 2023 Show Adult Obesity Prevalence Remains High
New CDC population data from 2023 show that in 23 states more than one in three adults (35%) has obesity. Before 2013, no state had an adult obesity prevalence at or above 35%. Currently, at least one ...
LeaderMed Group and Combiphar Form Joint Venture on LM-008, a Novel GLP-1 Dual Agonist, Targeting Indonesia's High Diabetes and/or Obesity Prevalence
JAKARTA, Indonesia and NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- (LeaderMed), a global pharmaceutical development company, and Combiphar, a leading Indonesian pharmaceutical company in Southeast ...